Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$20.29
+2.5%
$20.86
$19.00
$26.58
$2.48B0.851.39 million shs2.48 million shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$60.76
+0.9%
$58.33
$1.16
$14.10
$58.49M-0.12189,291 shs196,285 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$17.14
+6.3%
$16.31
$12.72
$34.47
$2.81B0.451.33 million shs2.07 million shs
Organogenesis stock logo
ORGO
Organogenesis
$5.00
-0.6%
$4.62
$2.45
$6.71
$638.09M1.75722,645 shs402,012 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
+2.47%-1.46%-6.88%-21.57%+1.91%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-2.27%+0.40%-1.05%+20.33%+21.33%
Immunovant, Inc. stock logo
IMVT
Immunovant
+6.33%+16.68%+7.39%+2.21%-44.15%
Organogenesis stock logo
ORGO
Organogenesis
-0.60%-2.91%+11.11%+65.02%+85.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$20.29
+2.5%
$20.86
$19.00
$26.58
$2.48B0.851.39 million shs2.48 million shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$60.76
+0.9%
$58.33
$1.16
$14.10
$58.49M-0.12189,291 shs196,285 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$17.14
+6.3%
$16.31
$12.72
$34.47
$2.81B0.451.33 million shs2.07 million shs
Organogenesis stock logo
ORGO
Organogenesis
$5.00
-0.6%
$4.62
$2.45
$6.71
$638.09M1.75722,645 shs402,012 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
+2.47%-1.46%-6.88%-21.57%+1.91%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-2.27%+0.40%-1.05%+20.33%+21.33%
Immunovant, Inc. stock logo
IMVT
Immunovant
+6.33%+16.68%+7.39%+2.21%-44.15%
Organogenesis stock logo
ORGO
Organogenesis
-0.60%-2.91%+11.11%+65.02%+85.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.13
Buy$33.2063.63% Upside
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
2.83
Moderate Buy$33.6096.03% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5050.00% Upside

Current Analyst Ratings Breakdown

Latest ORGO, GMTX, IMVT, and CPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00
8/19/2025
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/12/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$40.00 ➝ $37.00
8/12/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$33.00 ➝ $30.00
8/11/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$7.00 ➝ $9.00
7/28/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$17.00 ➝ $18.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$7.00
7/10/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold$18.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$558.50M4.45$2.51 per share8.09$6.10 per share3.33
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.16 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.32$0.21 per share24.10$2.09 per share2.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$163.89M$1.6512.309.530.8037.36%40.78%35.36%11/5/2025 (Estimated)
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)

Latest ORGO, GMTX, IMVT, and CPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q1 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.69-$0.60+$0.09-$0.71N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
6.71
6.55
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
12.32
12.32
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Organogenesis stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.80%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80122.39 million109.66 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120174.32 million171.18 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable

Recent News About These Companies

Nuveen LLC Purchases New Shares in Organogenesis $ORGO
Organogenesis: Transformational Changes Taking Shape
Organogenesis Amends Credit Agreement Amid Revenue Decline
ORGO Sales Drop 23%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.29 +0.49 (+2.47%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$20.42 +0.13 (+0.62%)
As of 09/5/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$60.76 +0.57 (+0.95%)
As of 09/5/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$17.14 +1.02 (+6.33%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$17.23 +0.09 (+0.50%)
As of 09/5/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$5.00 -0.03 (-0.60%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$4.97 -0.03 (-0.60%)
As of 09/5/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.